# Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

> **NCT05396833** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Metastatic or Locally Advanced Unresectable Solid Tumors

## Interventions

- **DRUG:** Tuvusertib
- **DRUG:** Lartesertib
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT05396833
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-07
- **Primary completion:** 2026-04-10
- **Final completion:** 2026-04-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396833, "Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05396833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*